Developments in identifying and managing mucormycosis in hematologic cancer patients.

Developments in identifying and managing mucormycosis in hematologic cancer patients. Expert Rev Hematol. 2020 Jul 15;: Authors: Pagano L, Dragonetti G, de Carolis E, Veltri G, Del Principe MI, Busca A Abstract INTRODUCTION: Mucormycoses represent a rare but very aggressive class of mold infections occurring in patients with hematological malignancies (HMs). In the past, hematologic patients at high risk of invasive mucomycosis (IM) were those affected by acute myeloid leukemia but over the last ten years the prophylaxis with a very effective mold-active drug such as posaconazole, has completely modified the epidemiology. In fact, IM is now observed more frequently in patients with lymphoproliferative disorders who do not receive antifungal prophylaxis. AREAS COVERED: The attention was focused on the epidemiology, diagnosis, prophylaxis and treatment of IM in HMs. Authors excluded pediatric patients considering the different epidemiology and differences in treatment given the limitation of the use of azoles in the pediatric field. A systematic literature review was performed using PubMed database listings between February 2014 and February 2020 using the following MeSH terms: leukemia, hematological malignancies, stem cell transplantation, mucormycosis, molds, prophilaxis, treatment. The authors reviewed all the publications identified and prepared their paragraph. After a common revision according to the results of the plena...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research